SCHEMBL4416451

SCHEMBL4416451

O=C1NC(=S)S/C1=C/c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NAT1 P18440 7/20 1.00
CA2 P00918 1/20 1.00
EPHX1 P07099 1/20 1.00
MMP3 P08254 2/20 0.75
MMP13 P45452 2/20 0.75
PIM1 P11309 2/20 0.71
PIM3 Q86V86 1/20 0.71
PIM2 Q9P1W9 1/20 0.71
CISD1 Q9NZ45 4/20 0.71
MYC P01106 2/20 0.71
MAOA P21397 1/20 0.71
MAX P61244 1/20 0.71
IL1RN P18510 1/20 0.69
ERAP1 Q9NZ08 1/20 0.69
MEN1 O00255 1/20 0.68
RAB9A P51151 1/20 0.68
KMT2A Q03164 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1812224 1.00 NAT1 (1.00) NAT1CA2EPHX1MMP3MMP13
SCHEMBL3491175 1.00 NAT1 (1.00) NAT1CA2EPHX1MMP3MMP13
SCHEMBL1247510 0.90 NAT1 (1.00) NAT1CA2EPHX1MMP3MMP13
SCHEMBL10596480 0.90 NAT1 (1.00) NAT1CA2EPHX1MMP3MMP13
SCHEMBL1247509 0.90 NAT1 (1.00) NAT1CA2EPHX1MMP3MMP13
SCHEMBL8173568 0.86 NAT1 (0.75) NAT1CA2EPHX1MMP3MMP13
SCHEMBL18103088 0.86 MMP3 (1.00) NAT1CA2EPHX1MMP3MMP13
SCHEMBL18102890 0.86 NAT1 (0.76) NAT1CA2EPHX1MMP3MMP13
SCHEMBL8173565 0.86 NAT1 (0.75) NAT1CA2EPHX1MMP3MMP13
SCHEMBL19991267 0.86 NAT1 (0.76) NAT1CA2EPHX1MMP3MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1654380-A4 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING HEPARANASE ACTIVATION AND USES THEREOF INSIGHT BIOPHARMACEUTICALS LTD (IL) 2009-09-09 EP disclosed
US-RE40603-E1 Silver halide photographic light-sensitive material FUJIFILM CORPORATION (JP) 2008-12-09 US disclosed
US-20080051445-A1 2-Thioxothiazolidin-4-one compounds and compositions as antimicrobial and antimalarial agents targeting enoyl-ACP reductase of type II fatty acid synthesis pathway and other cell growth pathways NATIONAL INSTITUTE OF IMMUNOLOGY. 2008-02-28 US disclosed
EP-1834642-A2 2-thioxothiazolidin-4-one compounds and compositions as antimicrobial and antimalarial agents targeting enoyl-ACP reductase of type II fatty acid synthesis pathway and other cell growth pathways National Institute of Immunology (IN) 2007-09-19 EP disclosed
EP-1654380-A2 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING HEPARANASE ACTIVATION AND USES THEREOF Insight Biopharmaceuticals Ltd. (IL) 2006-05-10 EP disclosed
US-6911303-B2 Light-sensitive silver halide grain FUJI PHOTO FILM, CO., LTD. (JP) 2005-06-28 US disclosed
WO-2005016227-A2 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING HEPARANASE ACTIVATION AND USES THEREOF INSIGHT BIOPHARMACEUTICALS LTD. (IL) 2005-02-24 WO disclosed
US-20050042213-A1 Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof INSIGHT BIOPHARMACEUTICALS LTD. 2005-02-24 US disclosed
US-6723496-B2 COMPLEX FUJI PHOTO FILM CO., LTD. (JP) 2004-04-20 US disclosed
US-20030186179-A1 Light-sensitive silver halide grain FUJI PHOTO FILM CO., LTD. 2003-10-02 US disclosed
US-5457106-A Antiinflammatory agents TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1995-10-10 US disclosed
EP-0659883-A2 Protein p140 and DNA encoding it ONO PHARMACEUTICAL CO., LTD. (JP) 1995-06-28 EP disclosed
EP-0658802-A2 Surface latent image type photographic material containing silver halide grains doped with cyano-chromium-complex ion FUJI PHOTO FILM CO., LTD. (JP) 1995-06-21 EP disclosed
US-5389658-A Administering as antipyretic, antiinflammatory, analgesic, antiallergic, or immunosupressive agents TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1995-02-14 US disclosed
EP-0612729-A2 Pyridine derivatives, their production and use Takeda Chemical Industries, Ltd. (JP) 1994-08-31 EP disclosed
US-5266457-A Phosphine sulfide as sensitizer FUJI PHOTO FILM CO., LTD. (JP) 1993-11-30 US disclosed
US-5246948-A Antiinflammatory, antipyretic, analgesic, antiallergic, immunosupressing or immunomodulating activity TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1993-09-21 US disclosed
EP-0522606-A2 Pyridine derivatives, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1993-01-13 EP disclosed
US-4018891-A INHIBITORS OF ANTIGEN-ANTIBODY REACTIONS RICHARDSON-MERRELL INC. (US) 1977-04-19 US disclosed
US-3960892-A ANTIGEN-ANTIBODY REACTION INHIBITION RICHARDSON-MERRELL INC. (US) 1976-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050042213-A1 Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof HPSE, HPN, ENGASE NAT1 1754/4885CA2 777/4885EPHX1 382/4885
US-20080051445-A1 2-Thioxothiazolidin-4-one compounds and compositions as antimicrobial and antimalarial agents targeting enoyl-ACP reductase of type II fatty acid synthesis pathway and other cell growth pathways FASN, FADS2, TECR NAT1 77/4885CA2 3072/4885EPHX1 1432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.